Verismo Therapeutics

Executive Summary

Verismo Therapeutics is a clinical-stage biotechnology company pioneering a novel KIR-CAR T cell therapy platform, SynKIR™, designed to treat solid tumors. The company's technology features a multi-chain immunoreceptor construct based on natural killer (NK) cell receptors, which aims to reduce T cell exhaustion and improve persistence in the challenging solid tumor microenvironment. Founded in 2018, the company is advancing its lead candidates through initial clinical trials. Verismo's differentiated approach addresses key limitations of conventional CAR-T therapies in solid tumors, including poor persistence and T cell exhaustion. The company's preclinical data support the potential of SynKIR™-based therapies to overcome these challenges, positioning it as a promising player in the cell therapy landscape. However, as a preclinical-stage company with no disclosed funding rounds or partnerships, Verismo faces significant execution risk and will require substantial capital to advance its pipeline into clinical development and ultimately to commercialization.

Upcoming Catalysts (preview)

• Q3 2026IND Filing for Lead Candidate70% success
• TBDInitial Phase 1 Clinical Data Readout40% success
• Q4 2026Strategic Partnership or Licensing Deal30% success